Abstract Number: 881 • 2014 ACR/ARHP Annual Meeting
DNA Methylation Analysis of the Temporal Artery Microenvironment Reveals a Robust T Cell Signature and Suggests a Role for TNF-α in Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a systemic large vessel vasculitis of unknown etiology. A hallmark of GCA is the presence of granulomatous inflammation of…Abstract Number: 880 • 2014 ACR/ARHP Annual Meeting
An Immunochip Study Confirms a Strong Contribution of HLA Class I and II Genes in the Susceptibility to Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a chronic autoimmune vasculitis with an important genetic component. We aimed to identify relevant risk loci for GCA predisposition…Abstract Number: 899 • 2014 ACR/ARHP Annual Meeting
Insurance Status and U.S. Region Associated with Placement of Permanent Vascular Access in Dialysis Patients with End-Stage Renal Disease Secondary to Lupus Nephritis
Background/Purpose: Prior data suggest sociodemographic and regional variability in various indicators of quality of end-stage renal disease (ESRD) care, both overall and in the SLE…Abstract Number: 898 • 2014 ACR/ARHP Annual Meeting
Traditional Cardiovascular Risk-Factor Management in Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients in a US Managed Care Setting
Background/Purpose: Studies have suggested suboptimal care of traditional cardiovascular risk factors (CRF) in patients (pts) with RA as a reason for elevated CV risk compared…Abstract Number: 882 • 2014 ACR/ARHP Annual Meeting
A Signature of microRNAs Overexpressed in Inflamed Temporal Arteries of Patients with Giant Cell Arteritis
Background/Purpose: MicroRNAs (miRNAs) are small, non-coding RNAs that suppress gene expression at post-transcriptional level. MiRNAs can regulate innate and adaptive immunity. Moreover, they have been…Abstract Number: 878 • 2014 ACR/ARHP Annual Meeting
Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment
Background/Purpose Tyrosine kinase inhibitors (TKIs), including imatinib mesylate, have been studied for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc). In a previously reported single…Abstract Number: 877 • 2014 ACR/ARHP Annual Meeting
Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts
Background/Purpose Systemic sclerosis (SSc) is a connective tissue disease characterized by inflammation, vasculopathy and fibrosis. Tissue fibrosis directly contributes to mortality or quality of life.…Abstract Number: 876 • 2014 ACR/ARHP Annual Meeting
SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study
Background/Purpose Preclinical genetic and pharmacological studies suggest a role for Lysophosphatidic acid (LPA) involvement in three key processes of systemic sclerosis: fibrosis, microangiopathy and immunoinflammation.…Abstract Number: 875 • 2014 ACR/ARHP Annual Meeting
Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials
Background/Purpose: Recent studies have shown that therapies for pulmonary arterial hypertension (PAH) improve exercise capacity, but subgroup analyses suggest that these therapies may be less…Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…Abstract Number: 873 • 2014 ACR/ARHP Annual Meeting
The Second Messenger, Cyclic GMP-AMP Dinucleotide (cGAMP) and the Enzyme, Cyclic GMP-AMP Synthase (cGAS), Are Expressed in Systemic Lupus Erythematosus
Background/Purpose: The type I IFNs (IFN-I), are strongly associated with Systemic Lupus Erythematosus (SLE). It is generally considered that IFN-I is induced by immune complexes…Abstract Number: 872 • 2014 ACR/ARHP Annual Meeting
Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia
Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in…Abstract Number: 871 • 2014 ACR/ARHP Annual Meeting
Antimalarials Regulate TLR7/8 Mediated Macrophage Activation Via Epigenetic Modification at the TNFα Promoter
Background/Purpose: Maternal anti-SSA autoantibodies contribute to the pathogenesis of congenital heart block by the formation of immune complexes (IC) comprised of Ro and ssRNA (hY3)…Abstract Number: 870 • 2014 ACR/ARHP Annual Meeting
IRF1 Influences on Histone H4 Acetylation in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease. Epigenetic processes, such as posttranslational histone modifications, can regulate gene expression without altering the…Abstract Number: 869 • 2014 ACR/ARHP Annual Meeting
UBE2L3 genotype Influences Plasma Cell Proliferation in Systemic Lupus Erythematosus By Regulation of NF-κB By the Linear Ubiquitination Assembly Complex
Background/Purpose: Genome-wide association studies have identified a strong association between a single risk haplotype of the UBE2L3gene and Systemic Lupus Erythematosus (SLE), as well as…
ACR Meeting Abstracts